

iBio, Inc.  
Form 10-Q/A  
February 17, 2010

---

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington D.C. 20549**  
**FORM 10-Q/A**

**Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

For the quarterly period ended September 30, 2009

**OR**

**Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 000-53125

**iBio, Inc.**

*(Exact name of small business registrant in its charter)*

**Delaware**

*(State or other jurisdiction of  
incorporation or organization)*

**9 Innovation Way, Suite  
100, Newark, DE**

*(Address of principal executive  
offices)*

**(302) 355-0650**

*(Registrant's telephone number, including Area Code)*

**26-2797813**

*(I.R.S. Employer Identification  
No.)*

**19711**

*(Zip Code)*

**Not Applicable**

*(Former name, former address and former fiscal year, if changed since last report)*

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Edgar Filing: iBio, Inc. - Form 10-Q/A

Yes

No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes

No

The number of shares outstanding of each of the issuer's class of common stock, as of the latest practicable date:

| <i>Class</i>                    | <i>Outstanding at November 12, 2009</i> |
|---------------------------------|---|
| Common Stock, \$0.001 par value | 27,972,904 Shares                       |

**iBio, Inc.**  
**(Formerly iBioPharma, Inc.)**  
**FORM 10-Q/A**  
**For the Three Months Ended September 30, 2009**

**INDEX**

|  | Page   |
|--|--|
| <b><u>Part I - FINANCIAL INFORMATION</u></b> |  |
| <b><u>Item 1</u></b>                         | <b><u>Financial Statements (Unaudited):</u></b>  |
|  | <u>Condensed Balance Sheets</u> 2  |
|  | <u>Condensed Statements of Operations</u> 3  |
|  | <u>Condensed Statement of Stockholders' Equity</u> 4   |
|  | <u>Condensed Statements of Cash Flows</u> 5  |
|  | <u>Notes to Condensed Financial Statements</u> 6   |
| <b><u>Item 2</u></b>                         | <b><u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b> 15 |
| <b><u>Item 3</u></b>                         | <b><u>Quantitative and Qualitative Disclosures About Market Risks</u></b> 18                           |
| <b><u>Item 4T</u></b>                        | <b><u>Controls and Procedures</u></b> 19   |
| <b><u>Part II - OTHER INFORMATION</u></b>    |  |
| <b><u>Item 1</u></b>                         | <b><u>Legal Proceedings</u></b> 20   |
| <b><u>Item 1A</u></b>                        | <b><u>Risk Factors</u></b> 20  |
| <b><u>Item 2</u></b>                         | <b><u>Unregistered Sales of Equity Securities and Use of Proceeds</u></b> 20                           |
| <b><u>Item 3</u></b>                         | <b><u>Defaults Upon Senior Securities</u></b> 20   |
| <b><u>Item 4</u></b>                         | <b><u>Submission of Matters to a Vote of Security Holders</u></b> 20                                   |
| <b><u>Item 5</u></b>                         | <b><u>Other Information</u></b> 20   |
| <b><u>Item 6</u></b>                         | <b><u>Exhibits</u></b> 21  |
| <b><u>Signatures</u></b>                     | 21   |

---

**DISCLOSURE REGARDING FORWARD-LOOKING FINANCIAL STATEMENTS**

Certain statements in this Quarterly Report on Form 10-Q/A may constitute forward-looking statements as defined in Section 27A of the Securities Act of 1933 (the Securities Act ), Section 21E of the Securities Act of 1934 (the Exchange Act ), the Private Securities Litigation Reform Act of 1995 (the PSLRA ) or in releases made by the Securities and Exchange Commission, all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of iBio, Inc. or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements that are not historical fact are forward-looking statements. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as the words, plan , believe , expect , anticipate , intend , estimate , project , may , will , would , could , should , seeks , or scheduled to , or other similar terms or other variations of these terms or comparable language, or by discussion of strategy or intentions. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the safe harbor provisions of such laws.

iBio, Inc. (the Company ) cautions investors that any forward-looking statements made by the Company are not guarantees or indicative of future performance. Important assumptions and other important factors that could cause actual results to differ materially from those forward-looking statements with respect to the Company, include, but are not limited to, the risks and uncertainties affecting its business described in Item 1 of the Company s Annual Report filed on Form 10-K for the year ended June 30, 2009 and in registration statements and other securities filings by the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any of its forward-looking statements, which are subject to change and inherent risks and uncertainties.

The forward-looking statements contained in this Quarterly Report on Form 10-Q/A are made only as of the date hereof and the Company does not have or undertake any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

**EXPLANATORY NOTE**

This Amendment No. 1 to Form 10-Q/A for reflects the restatement of the financial statements for the three month period ended September 30 2009 related to the adoption of the guidance in Accounting Standards Codification 815-40, Derivatives and Hedging - Contracts in Entity s Own Equity as of July 1, 2009. Accordingly, Part I Item 2, Management s Discussion and Analysis of Financial Condition and Results of Operations, Part I Item 4T, Controls and Procedures, and the Certifications referenced in Part II Item 6 have been updated in this connection.

This Amendment speaks as of the original filing of our Form 10-Q and has not been updated to reflect events occurring subsequent to the original filing date.

**PART I FINANCIAL INFORMATION****Item 1 FINANCIAL STATEMENTS**

**iBio, Inc.**  
**(Formerly iBioPharma, Inc.)**  
**Condensed Balance Sheets**

|  | September 30,<br>2009<br>(Unaudited)<br>(Restated) | June 30,<br>2009<br>(Note 2) |
|--|--|------------------------------|
| <b>Assets</b>  |  |                              |
| Current assets:  |  |                              |
| Cash   | \$ 3,376,995                                       | \$ 1,039,244                 |
| Accounts receivable  | 205,868  | 209,795                      |
| Prepaid expenses and other current assets  | 70,924   | 16,569                       |
| <br>   |  |                              |
| Total current assets   | 3,653,787  | 1,265,608                    |
| Fixed assets, net  | 13,921   | 14,878                       |
| Intangible assets, net   | 3,782,262  | 3,649,878                    |
| <br>   |  |                              |
| Total assets   | \$ 7,449,970                                       | \$ 4,930,364                 |
| <b>Liabilities and Stockholders Equity</b>   |  |                              |
| Current liabilities:   |  |                              |
| Accounts payable and accrued expenses  | \$ 776,583   | \$ 542,140                   |
| Derivative instrument liability (see Note 6)   | 1,181,960  | -                            |
| <br>   |  |                              |
| Total liabilities  | 1,958,543  | 542,140                      |
| <br>   |  |                              |
| Commitments and contingencies  |  |                              |
| <br>   |  |                              |
| Stockholders equity  |  |                              |
| Preferred stock, no par value, 5,000,000 shares authorized, no shares outstanding  | -  | -                            |
| Common stock, \$0.001 par value, 50,000,000 shares authorized, 27,972,904 and 23,357,519 issued and outstanding as of September 30, 2009 and June 30, 2009, respectively | 27,973   | 23,358                       |
| Additional paid-in capital   | 14,449,288   | 13,049,734                   |
| Accumulated deficit  | (8,985,834)  | (8,684,868)                  |
| <br>   |  |                              |
| Total stockholders equity  | 5,491,427  | 4,388,224                    |

Edgar Filing: iBio, Inc. - Form 10-Q/A

|  |    |           |    |           |
|--|----|-----------|----|-----------|
| Total liabilities and stockholders' equity | \$ | 7,449,970 | \$ | 4,930,364 |
|--|----|-----------|----|-----------|

The accompanying notes are an integral part of these  
unaudited condensed financial statements

**iBio, Inc.**  
**(Formerly iBioPharma, Inc.)**  
**Condensed Statements of Operations**  
**(Unaudited)**

|  | Three months ended September 30, |              |
|--|----------------------------------|--------------|
|  | 2009<br>(Restated)               | 2008         |
| Sales  | \$ -                             | \$ 333,428   |
| Cost of goods sold   | -                                | 135,648      |
| Gross profit   | -                                | 197,780      |
| Operating expenses:  |                                  |              |
| Research and development   | 104,212                          | 323,985      |
| General and administrative   | 468,207                          | 423,413      |
| Total operating expenses   | 572,419                          | 747,398      |
| Operating loss   | (572,419)                        | (549,618)    |
| Other income (expense):  |                                  |              |
| Interest income  | 2,098                            | 7,354        |
| Royalty income   | 9,130                            | -            |
| Change in fair value of derivative instrument liability (see Note 6) | (982,571)                        | -            |
| Other income   | (971,343)                        | 7,354        |
| Loss before income taxes   | (1,543,762)                      | (542,264)    |
| Income tax expense   | 600                              | 1,040        |
| Net loss   | \$ (1,544,362)                   | \$ (543,304) |
| Net loss per common share - Basic and diluted                        | \$ (0.06)                        | \$ (0.05)    |
| Weighted average common shares outstanding - Basic and diluted       | 24,360,864                       | 10,963,894   |

The accompanying notes are an integral part of these  
unaudited condensed financial statements

**iBio, Inc.**  
**(Formerly iBioPharma, Inc.)**  
**Condensed Statement of Stockholders Equity**  
**(Unaudited)**  
**(Restated)**

|   | Preferred Stock |        | Common Stock |           | Additional<br>Paid-In<br>Capital | Accumulated<br>Deficit | Total        |
|---|-----------------|--------|--------------|-----------|----------------------------------|------------------------|--------------|
|   | Shares          | Amount | Shares       | Amount    |                                  |                        |              |
| Balance, June 30, 2009 and July 1, 2009 as previously reported  | -               | \$ -   | 23,357,519   | \$ 23,358 | \$ 13,049,734                    | \$ (8,684,868)         | \$ 4,388,224 |
| Cumulative effect of restatement for a change in accounting principle - Adoption of ASC 815-40 (see Note 6) | -               | -      | -            | -         | (1,442,785)                      | 1,243,396              | (199,389)    |
| Balance, July 1, 2009 as restated   | -               | -      | 23,357,519   | 23,358    | 11,606,949                       | (7,441,472)            | 4,188,835    |
| Issuance of common stock and warrants for cash at \$0.65 per share, net of expenses                         | -               | -      | 4,615,385    | 4,615     | 2,802,436                        | -                      | 2,807,051    |
| Stock-based compensation expense  | -               | -      | -            | -         | 14,303                           | -                      | 14,303       |
| Issuance of warrants to consultant  | -               | -      | -            | -         | 25,600                           | -                      | 25,600       |
| Net loss  | -               | -      | -            | -         | -                                | (1,544,362)            | (1,544,362)  |
| Balance, September 30, 2009   | -               | \$ -   | 27,972,904   | \$ 27,973 | \$ 14,449,288                    | \$ (8,985,834)         | \$ 5,491,427 |

The accompanying notes are an integral part of these  
unaudited condensed financial statements



**iBio, Inc.**  
**(Formerly iBioPharma, Inc.)**  
**Condensed Statements of Cash Flows**  
**(Unaudited)**

|  | Three months ended September<br>30, |                  |
|--|-------------------------------------|------------------|
|  | 2009<br>(Restated)                  | 2008             |
| <b>Cash flows from operating activities:</b>                                       |                                     |                  |
| Net loss   | \$ (1,544,362)                      | \$ (543,304)     |
| <b>Adjustments to reconcile net loss to net cash used in operating activities:</b> |                                     |                  |
| Change in fair value of derivative instrument liability (see Note 6)               | 982,571                             | -                |
| Depreciation and amortization  | 78,436                              | 64,431           |
| Stock-based compensation   | 14,303                              | 4,763            |
| Issuance of warrants for services  | 25,600                              | -                |
| <b>Changes in operating assets and liabilities:</b>                                |                                     |                  |
| (Increase) decrease in accounts receivable   | 3,927                               | (199,108)        |
| (Increase) decrease in prepaid expenses and other current assets                   | (54,355)                            | 1,098            |
| Increase (decrease) in accounts payable and accrued expenses                       | 234,443                             | (105,972)        |
| <br>Net cash used in operating activities  | <br>(259,437)                       | <br>(778,092)    |
| <b>Cash flows from investing activities:</b>                                       |                                     |                  |
| Additions to intangible assets   | (209,863)                           | (883,891)        |
| <br>Net cash used in investing activities  | <br>(209,863)                       | <br>(883,891)    |
| <b>Cash flows from financing activities:</b>                                       |                                     |                  |
| Proceeds from sale of common stock and warrants, net of expenses                   | 2,807,051                           | 4,580,302        |
| Advances from former parent, net   | -                                   | 82,083           |
| <br>Net cash provided by financing activities                                      | <br>2,807,051                       | <br>4,662,385    |
| <br>Net increase in cash   | <br>2,337,751                       | <br>3,000,402    |
| Cash - Beginning of period   | 1,039,244                           | 19,005           |
| <br>Cash - End of period   | <br>\$ 3,376,995                    | <br>\$ 3,019,407 |

**Supplemental disclosures of cash flow information:**

Cash paid for:

Edgar Filing: iBio, Inc. - Form 10-Q/A

|   |    |         |    |           |
|---|----|---------|----|-----------|
| Interest  | \$ | -       | \$ | -         |
| Income taxes  | \$ | -       | \$ | 1,040     |
| Supplemental disclosures of non-cash investing and financing activities:                    |    |         |    |           |
| Cumulative effect of a change in accounting principle - Adoption of ASC 815-40 (see Note 6) | \$ | 199,389 | \$ | -         |
| Cancellation of common stock owned by former parent   | \$ | -       | \$ | 575,000   |
| Issuance of common stock to stockholders of former parent                                   | \$ | -       | \$ | 19,845    |
| Issuance of common stock upon conversion of intercompany debt due to former parent          | \$ | -       | \$ | 7,909,494 |

The accompanying notes are an integral part of these  
unaudited condensed financial statements

**iBio, Inc.**  
**(Formerly iBioPharma, Inc.)**  
**Notes to Condensed Financial Statements**  
**(Unaudited)**

**1) Business**

iBio, Inc. (the Company) is a biotechnology company focused on developing vaccines and therapeutic proteins based upon its proprietary plant-based technology. The Company's near-term focus is to advance influenza vaccine candidates to clinical trials and to establish business arrangements for use of its technology by licensees for the development and production of products for the prevention and treatment of various infectious diseases. Vaccine candidates presently being advanced on the Company's proprietary platform are applicable to newly emerging strains of H1N1 swine-like influenza and H5N1 for avian influenza.

Prior to April 1, 2009, the Company also used plants as a source of novel, high quality nutritional supplements and sold those products to customers located primarily in the United States. Effective on that date, the Company licensed that technology and transferred all such customer relationships to a subsidiary of its former parent in consideration for a 5% royalty on future net sales.

Effective August 10, 2009, the Company changed its name from iBioPharma, Inc. to iBio, Inc.

**2) Basis of Presentation**

The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q of the Securities and Exchange Commission. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America. However, in the opinion of management, the accompanying unaudited financial statements contain all normal and recurring adjustments necessary to present fairly the financial position of the Company as of September 30, 2009 and the related statements of operations and cash flows the three months ended September 30, 2008. The balance sheet amounts as of June 30, 2009 were derived from audited financial statements. For further information, refer to the audited financial statements and related disclosures that were filed by the Company with the Securities and Exchange Commission on Form 10-K for the fiscal year ended June 30, 2009.

Salaries and benefits totaling \$73,985 have been reclassified from general and administrative to research and development expense in the condensed statement of operations for the three months ended September 30, 2008 in order to conform to the current period presentation.

**3) Accounting Policies and Use of Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The areas most significantly affected by estimates consist of:

- a) Valuation and recovery of intangible assets;
- b) Contingent liabilities;
- c) Stock-based compensation; and
- d) Valuation of derivative instruments.

The Company's accounting policies and use of estimates are described in Note 2 to the audited financial statements contained in our Annual Report on Form 10-K for the year ended June 30, 2009 and, with respect to the valuation of derivative instruments, in Note 6 to these financial statements.

Management reviews its estimates on a continual basis utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.

**4) Earnings Per Share**

Basic and diluted net loss per common share was determined by dividing the net loss by the weighted average common shares outstanding during the three months ended September 30, 2009 and 2008. Basic and diluted weighted average common shares outstanding were the same since the effect of including common shares issuable pursuant to the exercise of the stock options and warrants in diluted weighted average common shares outstanding would have been anti-dilutive.

The following table summarizes the number of common shares excluded from the calculation of weighted average common shares outstanding for the three months ended September 30, 2009 and 2008:

|               | <u>2009</u>      | <u>2008</u>      |
|---------------|------------------|------------------|
| Warrants      | 3,065,811        | 2,345,752        |
| Stock options | 1,460,000        | -                |
| <b>Total</b>  | <b>4,525,811</b> | <b>2,345,752</b> |

**5) Recently Issued Accounting Pronouncements**

In June 2009, the Financial Accounting Standards Board ( FASB ) issued the FASB Accounting Standards Codification ( Codification or ASC ) as the single source of authoritative U.S. generally accepted accounting principles except for additional authoritative rules and interpretive releases issued by the SEC. The Codification is effective for financial statements issued for interim and annual periods ending after September 15, 2009. The Company adopted the Codification effective September 30, 2009 and such adoption did not have an impact upon the Company's financial statements.

Effective July 1, 2009, the Company adopted guidance in ASC 350-30, General Intangibles Other Than Goodwill . This guidance amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset. The adoption of this guidance did not have a material impact on our financial statements.

Effective July 1, 2009, the Company adopted guidance in ASC 815-40, Derivatives and Hedging - Contracts in Entity's Own Equity . This guidance was effective for fiscal years beginning after December 15, 2008 and the adoption by the Company effective July 1, 2009 had a material impact upon the Company's financial statements. The provisions of this guidance and details concerning its adoption are discussed in Note 6.

**6) Derivative Instruments and Related Restatement**

**Introduction:**

Effective July 1, 2009, generally accepted accounting principles required that the warrants issued by the Company in connection with the August 2008 financing to be considered derivative instruments and that the Company report an estimated fair value of such warrants as a liability as of each balance sheet date and the change in that liability as non-cash income or expense in the statement of operations for the related reporting period. The Company's financial statements as of and for the three months ended September 30, 2009 have been restated to reflect the adoption of this accounting guidance.

The Company uses the Black-Scholes option pricing model to estimate its derivative instrument liability which requires several assumptions, including the current price of the Company's common stock. This model is particularly sensitive to the assumed volatility in the price of the Company's common stock and the actual price of the Company's common stock as of each balance sheet date. Increases in the assumed volatility or the actual price of the Company's common stock has the effect of estimating a higher value for such warrants, which results in a larger estimated derivative liability on the balance sheet, which results in a larger non-cash expense being recorded in the statement of operations.

Thus, the accounting guidance applicable to these warrants requires the Company, (assuming all other inputs to the Black-Scholes model remain constant), to record a non-cash expense when the

## Edgar Filing: iBio, Inc. - Form 10-Q/A

Company's stock price is rising and recording non-cash income when the Company's stock price is falling.

### Detail Discussion:

Effective July 1, 2009, the Company adopted guidance in ASC 815-40, Derivatives and Hedging - Contracts in Entity's Own Equity. The applicable provisions of this guidance require that:

- a) Warrants issued by the Company in an August 2008 financing transaction containing downside ratchet provisions were previously accounted for as equity instruments in accordance with generally accepted accounting principles in effect through June 30, 2009. They must now be considered and accounted for as derivative instruments effective July 1, 2009 and the related fair value reported as a liability on the balance sheet; and
- b) Such derivative instruments must be marked-to-market at each balance sheet date and the change in the reported fair value of such instruments be recorded as non-cash income or expense in the statement of operations.

In accordance with this guidance, the Company estimated the fair value of these instruments to be \$199,389 as of July 1, 2009 and established a derivative instrument liability in that amount by recording reductions of \$1,442,785 in additional paid-in capital and \$1,243,396 in accumulated deficit. The effect of this adjustment is presented as a cumulative effect of a change in an accounting principle in the Company's condensed statement of stockholders' equity. As of September 30, 2009, the fair value of this derivative liability increased to \$1,181,960 and the resulting change of \$982,571 during the three months ended September 30, 2009 is reported as a non-cash charge in the Company's condensed statement of operations as a component of other income (expense).

The Company utilizes the Black-Scholes option pricing model to estimate the fair value of these derivative instruments. The Company considers them to be Level 2 type instruments in accordance with ASC 820-10 Fair Value Measurements and Disclosures as the inputs used to estimate their value are observable either directly or indirectly. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the remaining contractual term of the instruments. The expected volatility assumptions were based upon the historical volatility of the stock of comparable companies. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. The expected term assumptions were based upon the remaining contractual term of these instruments.

The assumptions made in calculating the fair value of these derivative instruments as of July 1, 2009 and September 30, 2009 were as follows:

|                         |                   |
|-------------------------|-------------------|
| Risk free interest rate | 1.9 and 2.0%      |
| Dividend yield          | Zero              |
| Volatility              | 80%               |
| Expected term           | 3.9 and 4.2 years |

## Edgar Filing: iBio, Inc. - Form 10-Q/A

The effect of this restatement as of and for the three months ended September 30, 2009 is summarized as follows (in thousands):

|  | As<br>Previously<br>Reported | Effect<br>Upon<br>Adoption | Effect<br>Upon<br>First<br>Quarter | As<br>Restated    |
|--|------------------------------|----------------------------|------------------------------------|-------------------|
| <b>Balance sheet:</b>                                |                              |                            |                                    |                   |
| Cash and other current assets                        | \$ 3,654                     | \$ -                       | \$ -                               | \$ 3,654          |
| Fixed assets   | 14                           | -                          | -                                  | 14                |
| Intangible assets                                    | 3,782                        | -                          | -                                  | 3,782             |
| <b>Total assets</b>                                  | <b>\$ 7,450</b>              | <b>-</b>                   | <b>-</b>                           | <b>\$ 7,450</b>   |
| Accounts payable and accrued expenses                | \$ 777                       | -                          | -                                  | \$ 777            |
| Derivative instrument liability                      | -                            | 199                        | 983                                | 1,182             |
| <b>Total liabilities</b>                             | <b>777</b>                   | <b>199</b>                 | <b>983</b>                         | <b>1,959</b>      |
| <b>Stockholders' equity:</b>                         |                              |                            |                                    |                   |
| Common stock   | 28                           | -                          | -                                  | 28                |
| Additional paid-in capital                           | 15,892                       | (1,443)                    | -                                  | 14,449            |
| Accumulated deficit                                  | (9,247)                      | 1,244                      | (983)                              | (8,986)           |
| <b>Total stockholders' equity</b>                    | <b>6,673</b>                 | <b>(199)</b>               | <b>(983)</b>                       | <b>5,491</b>      |
| <b>Total liabilities and stockholders' equity</b>    | <b>\$ 7,450</b>              | <b>\$ -</b>                | <b>\$ -</b>                        | <b>\$ 7,450</b>   |
| <b>Statement of Operations:</b>                      |                              |                            |                                    |                   |
| Revenues   | \$ -                         | \$ -                       | \$ -                               | \$ -              |
| <b>Operating expenses:</b>                           |                              |                            |                                    |                   |
| Research and development                             | 104                          | -                          | -                                  | 104               |
| General and administrative                           | 468                          | -                          | -                                  | 468               |
| <b>Operating loss</b>                                | <b>(572)</b>                 | <b>-</b>                   | <b>-</b>                           | <b>(572)</b>      |
| <b>Other income (expense):</b>                       |                              |                            |                                    |                   |
| Interest income                                      | 2                            | -                          | -                                  | 2                 |
| Royalty income                                       | 9                            | -                          | -                                  | 9                 |
| Change in fair value of derivative instruments       | -                            | -                          | (983)                              | (983)             |
| <b>Loss before income taxes</b>                      | <b>(561)</b>                 | <b>-</b>                   | <b>(983)</b>                       | <b>(1,544)</b>    |
| Income tax expense                                   | 1                            | -                          | -                                  | 1                 |
| <b>Net loss</b>                                      | <b>(\$ 562)</b>              | <b>\$ -</b>                | <b>(\$ 983)</b>                    | <b>(\$ 1,544)</b> |
| <b>Net loss per common share - Basic and diluted</b> | <b>(\$ 0.02)</b>             | <b>\$ -</b>                | <b>(\$ 0.04)</b>                   | <b>(\$ 0.06)</b>  |

## Statement of cash flows:

## Cash flows from operating activities:

|   |          |      |          |            |
|---|----------|------|----------|------------|
| Net loss  | (\$ 562) | \$ - | (\$ 983) | (\$ 1,544) |
| Adjustments to reconcile net loss to net cash used in operating activities: |          |      |          |            |
| Change in fair value of derivative instrument liability                     | -        | -    | 983      | 983        |
| Depreciation and amortization   | 78       | -    | -        | 78         |
| Stock-based compensation  | 14       | -    | -        | 14         |
| Issuance of warrants for services   | 26       | -    | -        | 26         |
| Changes in operating assets and liabilities (net)                           | 180      | -    | -        | 180        |
| Net cash used in operating activities                                       | (\$ 259) | \$ - | \$ -     | (\$ 259)   |

Note - Some amounts do not total exactly due to rounding.

## 7) Financing Transaction

On September 10, 2009, the Company issued 4,615,385 shares of common stock at \$0.65 per share and received net proceeds of \$2,807,051 and issued warrants to the placement agent for the purchase of 250,587 shares of common stock at a price of \$0.65 per share. The warrants were 100% vested upon issuance and expire on September 10, 2014. The Company estimated the fair value of the warrants, attributed proceeds of \$92,637 to them, and recorded that amount as an addition to paid-in capital.

Additionally, in connection with the September 2009 financing, the Company:

- a) Issued 299,751 shares of common stock to the investors in the August 2008 financing in accordance with the anti-dilution provisions of that offering. The Company accounted for the issuances of those shares as a reduction of additional paid-in capital and an increase in common stock at the aggregate par value of \$300; and
- b) Adjusted the warrant agreements with the investors in the August 2008 financing to provide for the purchase of an additional 369,472 shares of common stock and adjusted the exercise prices as follows:
  - i) Warrants for the purchase of 1,172,876 at \$3.20 per common share were revised to provide for the purchase of 1,350,073 at \$2.78 per common share; and



- ii) Warrants for the purchase of 1,172,876 at \$4.26 per common share were revised to provide for the purchase of 1,365,151 at \$3.66 per common share.

**8) Share Based Payments**

The Company measures the cost of services received in exchange for the award of equity instruments based upon the fair value of the award on the date of grant. The fair value of that award is then recognized as expense over the period during which the recipient is required to provide services in exchange for that award.

The Company utilizes the Black-Scholes option pricing model to estimate the fair value of such instruments. For instruments issued during the three month period ended September 30, 2009, the risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity instruments. The expected volatility assumption was based upon the historical volatility of the stock of comparable companies. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. The expected term assumption was determined utilizing the simplified method provided in Staff Accounting Bulletin No. 107, *Share-Based Payment*, which averages an award's vesting period with its contractual term.

Assumptions made in calculating the fair value of options and warrants issued during the three months ended September 30, 2009 and 2008 were as follows:

|                         | 2009             | 2008      |
|-------------------------|------------------|-----------|
| Risk free interest rate | 2.3 to 3.3%      | 3.1%      |
| Dividend yield          | Zero             | Zero      |
| Volatility              | 80%              | 80%       |
| Expected term           | 5.0 to 6.5 years | 5.0 years |

On July 13, 2009, the Company issued warrants to a third party for the purchase of 100,000 shares of common stock at a price of \$0.35 per share in connection with a professional service agreement. The warrants were 100% vested upon issuance and expire on July 13, 2014. The Company estimated the fair value of the warrants to be \$25,600 and accounted for them as an expense within general and administrative expenses on the date of issuance with a corresponding increase to additional paid-in capital.

On August 10, 2009, the Company granted options to members of management for the purchase of 500,000 shares of common stock at a price of \$0.66 per share. The options vest ratably on the first through fifth anniversary dates of the grant and expire on August 10, 2019. The Company estimated the fair value of the options on the grant date to be \$216,000 and is recording such expense ratably over the vesting period within general and administrative expenses.

On August 10, 2009, the Company granted options to members of the Board of Directors for the purchase of 180,000 shares of common stock at a price of \$0.66 per share. The options vest ratably on the first, second, and third anniversary dates of the grant and expire on August 10,

## Edgar Filing: iBio, Inc. - Form 10-Q/A

2019. The Company estimated the fair value of the options on the grant date to be \$77,760 and is recording such expense ratably over the vesting period within general and administrative expenses.

In connection with the financing transaction on September 10, 2009, the Company issued warrants to the placement agent for the purchase of 250,587 shares of common stock at a price of \$0.65 per share and adjusted the warrant agreements issued to the investors in the August 2008 financing to provide for the purchase of an additional 369,472 shares of common stock. See Note 7 for a detailed discussion of such issuances and adjustments.

A summary of the changes in options outstanding during the three month period ended September 30, 2009 is as follows:

|  | Number of<br>Shares | Exercise<br>Price<br>Per Share | Weighted<br>Average<br>Exercise<br>Price<br>Per Share | Weighted<br>Average<br>Remaining<br>Contractual<br>Term<br>(Years) | Aggregate<br>Intrinsic<br>Value |
|--|---------------------|--------------------------------|---|--|---------------------------------|
| Outstanding at June 30, 2009                           | 780,000             | \$ 0.20-\$0.31                 | \$ 0.21   | 9.6  | \$ 184,000                      |
| Granted  | 680,000             | \$ 0.66                        | \$ 0.66   | 10.0   | 353,600                         |
| Exercised  | -                   | -                              | -   | -  | -                               |
| Terminated   | -                   | -                              | -   | -  | -                               |
| Outstanding and expected to vest at September 30, 2009 | 1,460,000           | \$ 0.20-\$0.66                 | \$ 0.42   | 9.6  | \$ 1,107,000                    |

Options exercisable at September 30, 2009 -

The weighted average fair value of options granted during the three months ended September 30, 2009 was \$0.43.

A summary of the changes in warrants outstanding during the three months ended September 30, 2009 is as follows:

|                                   | Number of<br>Shares | Weighted<br>Average<br>Exercise<br>Price<br>Per Share |
|-----------------------------------|---------------------|---|
| Outstanding at June 30, 2009      | 2,345,752           | \$ 3.73   |
| Granted                           | 720,059             | 1.94  |
| Exercised                         | -                   | -   |
| Terminated                        | -                   | -   |
| Outstanding at September 30, 2009 | 3,065,811           | \$ 2.92   |

Warrants exercisable at September 30, 2009 3,065,811 \$ 2.92

### 9) Commitment

The Company and the Center for Molecular Biology of Fraunhofer USA, Inc. ( FhCMB ) have an agreement whereby FhCMB performs research and development activities on behalf of the Company. In that connection, the Company has the commitment to make payments of \$1

million in November 2009, May 2010, and other subsequent dates through May 2014 for an aggregate of \$10 million to FhCMB for services to further develop the Company's proprietary technology and product candidates.

**10) Contingency**

As of September 30, 2009, the Company and FhCMB disagree regarding whether a certain technical milestone has been achieved by FhCMB under a research agreement for vaccine studies which would trigger the obligation of a \$250,000 payment by the Company to FhCMB as of September 30, 2009. Management of both entities are working together to resolve this disagreement. If the Company recorded this obligation during the three months ended September 30, 2009, research and development expenses and the loss for the three months ended September 30, 2009 would have increased by \$250,000 and accrued liabilities at September 30, 2009 would have increased by the same amount.

**11) Subsequent Events**

The agreement with FhCMB described in Note 9 to these condensed financial statements provides for a payment of \$1.0 million to FhCMB on November 2, 2009 for research and development services to be rendered in the future. The Company is awaiting performance on the part of FhCMB with respect to certain deliverables previously due under the terms of the agreement before making this payment.

The Company has evaluated subsequent events through November 16, 2009, the date on which these condensed financial statements were issued. There have not been any other events subsequent to September 30, 2009 that would require additional disclosure in the condensed financial statements or that would have a material impact on the Company's condensed financial position as of September 30, 2009 and June 30, 2009, and its results of operations or cash flows for the three months ended September 30, 2009 and 2008.

**Item 2                    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Forward Looking Statements**

Certain statements set forth under this caption constitute forward-looking statements. See Disclosure Regarding Forward-Looking Statements on page 1 of this Report for additional factors relating to such statements. The following discussion should also be read in conjunction with the Condensed Financial Statements of the Company and Notes thereto included elsewhere herein and the Company's Annual Report on Form 10-K for the year ended June 30, 2009.

**Overview**

iBio, Inc. (the Company) is a biotechnology company focused on developing vaccines and therapeutic proteins based upon its proprietary plant-based technology. The Company's near-term focus is to advance influenza vaccine candidates to clinical trials and to establish business arrangements for use of its technology by licensees for the development and production of products for the prevention and treatment of various infectious diseases. Vaccine candidates presently being advanced on the Company's proprietary platform are applicable to newly emerging strains of H1N1 swine-like influenza and H5N1 for avian influenza.

In order to attract appropriate licensees and increase the value of the Company's share of such intended contractual arrangements, the Company engaged the Center for Molecular Biology of Fraunhofer USA, Inc. (FhCMB) in 2004 to perform research and development activities to apply the platform to create our first product candidate. The Company selected a plant-based influenza vaccine for human use as the product candidate to exemplify the value of the platform. Based on research conducted by FhCMB, our proprietary technology is applicable to the production of vaccines for any strain of influenza including the newly-emerged strains of H1N1 swine-like influenza.

In connection with the research and development agreement, FhCMB agreed to use its best efforts to obtain grants from governmental and non-governmental entities to fund additional development of our proprietary plant-based technology. Consequently, in addition to the funding we have provided, FhCMB has received funding from the Bill & Melinda Gates Foundation for development of an experimental vaccine for H5N1 avian influenza based upon our proprietary technology.

We expect at least one of these vaccine candidates to begin Phase 1 clinical trials during the calendar year 2010.

Current cash and working capital resources are expected to support our activities through the fall of 2010. We plan to fund our development and commercialization activities during the balance of 2010 and beyond through licensing arrangements and/or the sale of equity securities as more fully described in the *Liquidity and Capital Resources* section in the following paragraphs.

### Liquidity and Capital Resources

We had cash of \$3,377,000 at September 30, 2009 compared to \$1,039,000 at June 30, 2008. This increase of \$2,338,000, or 225%, was due to proceeds of \$2,807,000 from the sale of common stock offset by net cash used of \$259,000 and \$210,000 related to operating activities and investing activities, respectively. We had working capital of \$1,695,000 at September 30, 2009. The calculation of this working capital amount includes the derivative instrument liability of \$1,182,000 as of that date.

Current cash and working capital resources are expected to support our activities through the fall of 2010. This includes the commitment to make payments of \$1.0 million in November 2009, May 2010, and other subsequent dates through May 2014 for an aggregate of \$10 million to FhCMB for services to further develop the Company's proprietary technology and product candidates as more fully described in Note 9 to the accompanying condensed financial statements.

We plan to fund our development and commercialization activities during the balance of 2010 and beyond through licensing arrangements and/or the sale of equity securities. We cannot be certain that such funding will be available on acceptable terms, or available at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. If we are unable to raise funds when required or on acceptable terms, we may have to: a) Significantly delay, scale back, or discontinue the development and/or commercialization of one or more product candidates; b) Seek collaborators for product candidates at an earlier stage than would otherwise be desirable and/or on terms that are less favorable than might otherwise be available; or c) Relinquish or otherwise dispose of rights to technologies, product candidates, or products that we would otherwise seek to develop or commercialize ourselves.

### Critical Accounting Policies

The following accounting policies are critical in fully understanding and evaluating our financial statements:

- a) Valuation and recovery of intangible assets;
- b) Contingent liabilities;
- c) Stock-based compensation; and
- d) Valuation of derivative instruments.

The Company's accounting policies and use of estimates are described in Note 2 to the audited financial statements contained in our Annual Report on Form 10-K for the year ended June 30, 2009 and, with respect to the valuation of derivative instruments, in Note 6 to these financial statements.

Management reviews its estimates on a continual basis utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After

such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.

**Results of Operations**

*For the three months ended September 30, 2009 versus September 30, 2008*

Sales and cost of goods sold for the three months ended September 30, 2009 were both zero as compared to \$333,000 and \$136,000, respectively, for the comparable period in 2008. These decreases were attributable to the discontinuance of sales of nutritional supplements effective April 1, 2009. Effective on that date, the Company licensed that technology and transferred all such customer relationships to a subsidiary of its former parent in consideration for a 5% royalty on future net sales. That transaction relieved the Company of the prospective expenses associated with the sales, customer relations, and administrative burden of managing that business, financing its operations, and maintaining the related intellectual property.

Research and development expense for the three months ended September 30, 2009 was \$104,000 compared to \$324,000 for the comparable period in 2008. This decrease of \$220,000, or 68%, was due to a decrease of \$250,000 related to the absence of a milestone payment to FhCMB in 2009 comparable to one which occurred in 2008. This was offset by a net increase of \$30,000 consisting primarily of expense related to the preparation of an Investigational New Drug application (IND) filing with the United States Food and Drug Administration.

General and administrative expense for the three months ended September 30, 2009 was \$468,000 compared to \$423,000 for the comparable period in 2008. This increase of \$45,000, or 11%, was primarily due to an increase of \$56,000 in financial advisory fees, an increase of \$19,000 in accounting services, and a decrease of \$16,000 in legal services. Such increases reflected expenses associated with the Company now being a stand-alone public entity effective with the spin-off from its former parent in August 2008, while the decrease reflected the absence of legal services associated with the spin-off in August 2008.

Other income (expense) for the three months ended September 30, 2009 was (\$972,000) compared to \$7,000 the comparable period in 2008. This change consisted of the following income (expense):

|   | <u>2009</u>      | <u>2008</u>  |
|---|------------------|--------------|
| Interest income   | \$ 2,000         | \$ 7,000     |
| Royalty income  | 9,000            | -            |
| Change in the fair value of derivative instrument liability | (983,000)        | -            |
| <br>Total   | <br>(\$ 972,000) | <br>\$ 7,000 |

- a) Interest income decreased by \$5,000 reflecting the lower average balance of cash on hand during the comparable periods and lower interest rates.

- b) The presence of royalty income in 2009 when there was no comparable amount in 2008 relates to an agreement with a subsidiary of the Company's former parent which commenced in April 2009. (See the discussion in the sales and cost of goods sold paragraph above).
- c) The \$983,000 expense related to the change in the fair value of derivative financial instruments is recorded in accordance with the guidance in ASC 815-40, Derivatives and Hedging - Contracts in Entity's Own Equity which became effective for the Company on July 1, 2009 and is further discussed in Note 6 to these financial statements.

The accounting guidance applicable to these warrants, as described in Note 6, requires the Company, (assuming all other inputs to the Black-Scholes model remain constant), to record a non-cash expense when the Company's stock price is rising and recording non-cash income when the Company's stock price is falling. The estimated fair value of this derivative liability increased from \$199,000 at July 1, 2009 to \$1,182,000 at September 30, 2009 primarily as a result of an increase in our stock price during that same period. The resulting change of \$983,000 has been reported as non-cash expense in our condensed statement of operations as a component of other income (expense) and has no effect upon our operating cash flow.

The calculation of this derivative liability is affected by factors which are subject to significant fluctuations and are not under our control. Consequently, this liability and, therefore, the resulting effect of this expense upon our net loss is subject to significant fluctuations and will continue to be subject to significant fluctuations until the warrants either expire in August 2013 or are exercised prior to that date.

Income tax expense for the three months ended September 30, 2009 and 2008 reflects estimates for the minimum amounts of state income taxes due in states where we are required to file income tax returns. Our deferred tax assets resulting from our net operating losses are fully reserved in a valuation allowance account since it is more likely than not that such assets will not be realized.

**Item 3                    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

In the normal course of business, the Company may be a party to financial instruments that are subject to market risks arising from changes in interest rates and foreign currency rates. We currently do not use derivative financial instruments to address treasury risk management issues in connection with changes in interest rates and foreign currency rates.

**Item 4T            CONTROLS AND PROCEDURES**

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

As required by Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing and as described in the following paragraphs, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were not effective to ensure that information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.

Our independent public accounting firm, J.H. Cohn LLP ( JHC ), communicated to our audit committee on February 10, 2010 that a material weakness existed in our internal control over financial reporting. This weakness was comprised of financial accounting and disclosure deficiencies and financial reporting deficiencies for non-routine, complex transactions. This weakness resulted in additions and corrections to disclosures in our Form 10-Q prior to filing and in us not implementing the guidance in ASC 815-40, Derivative and Hedging Contracts in an Entity's Own Equity in a timely manner, which required the restatement of our financial statements as of and for the quarter ended September 30, 2009.

Upon receipt of the communication from JHC, management took immediate action to prospectively remediate this weakness by establishing an in-depth independent internal review that did not previously exist.

There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2009 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



**PART II OTHER INFORMATION**

**Item 1 LEGAL PROCEEDINGS**

We are not currently a party to any material legal proceedings.

**Item 1A RISK FACTORS**

The risks described in Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended June 30, 2009, could materially and adversely affect our business, financial condition and results of operations. The risk factors discussed in that Form 10-K do not identify all risks that we face because our business operations could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations.

Current economic conditions may cause a decline in business spending which could adversely affect our business and financial performance.

Our operating results are impacted by the health of the North American economies. Our business and financial performance, including collection of our accounts receivable and recoverability of assets including investments, may be adversely affected by current and future economic conditions, such as a reduction in the availability of credit, financial market volatility, and recession.

Additionally, we may experience difficulties in scaling our operations to react to economic pressures in the United States.

**Item 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

**Item 3 DEFAULTS UPON SENIOR SECURITIES**

None.

**Item 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS**

None.

**Item 5 OTHER INFORMATION**

None.

**Item 6            EXHIBITS**

**Exhibit  
Number**

- 31.1            Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.
- 31.2            Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer
- 32.1            Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.
- 32.2            Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

iBioPharma, Inc.

Date: February 16, 2010

By: /s/ Robert B. Kay  
Robert B. Kay,  
Chief Executive Officer

Date: February 16, 2010

By: /s/ Frederick Larcombe  
Frederick Larcombe,  
Chief Financial Officer